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The aim of present study was to elucidate the role of TAB1 in nitric oxide-induced activation of p38 MAPK. For 
this purpose we over-expressed TAB1 in insulin-producing β-TC6 cells. We observed in cells transiently over-
expressing TAB1 that p38 activation was enhanced in response to DETA/NONOate. A lowering of TAB1 levels, 
using the siRNA technique, resulted in the opposite effect. The DETA/NONOate-induced cell death rate was 
increased in cells transiently overexpressing TAB1. In stable β-TC6 cell clones with very high TAB1 levels p38 
phosphorylation was enhanced also at basal conditions. DETA/NONOate increased also the phosphorylation 
of JNK and ERK in β-TC6 cells, but these events were not affected by TAB1. Interestingly, the inhibitory effect 
of SB203580 on p38 phosphorylation was paralleled by a stimulatory effect on JNK phosphorylation and an 
inhibitory effect on ERK phosphorylation. In summary, we propose that TAB1 promotes nitric oxide-induced 
p38 autophosphorylation. In addition, nitric oxide-induced p38 activation seems to promote JNK inhibition and 
ERK activation, but this effect appears to not require TAB1. A better understanding of how the TAB1/p38 
pathway promotes β-cell death in response to nitric oxide might help in the development of novel 
pharmacological approaches in the treatment of diabetes. 
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1.  Introduction 
Type 1 diabetes is an autoimmune disease 
leading to extensive destruction of the pancreatic β-
cells. Cell dysfunction and damage may result from 
direct contact with islet-infiltrating macrophages and 
T cells and/or exposure to soluble products of these 
cells, such as cytokines and free radicals. The radical 
nitric oxide (NO) is a possible mediator of pancreatic 
β-cell damage in insulin-dependent diabetes mellitus 
[1]. Increased production of NO, mediated by the 
inducible isoform of NO synthase (iNOS), in response 
to pro-inflammatory cytokines occurs not only in 
insulin producing β-cells [2], but also activated duct 
cells [3], macrophages [4] and endothelial cells [5] that 
are present in the islet micro-environment. NO 
participates in the regulation of the physiological 
activities of cells as well as in cytotoxic events. It 
possesses a biphasic effect on cell viability by both 
protecting against pro-apoptotic stimuli at moderate 
concentrations, and by inducing apoptosis when 
produced at high concentrations [6]. NO-induced cell 
death may involve multiple signaling pathways [7]. 
For example, NO has been shown to activate caspases 
and the tumor supressor p53, and down-regulate Bcl-
2 [8,9]. NO-production inhibits the mitochondrial 
enzyme aconitase in rodent islet cells, leading to a 
suppressed mitochondrial activity and a defective 
insulin release [2,10]. We have also observed that NO-
production results in a transient increase in p53 levels 
in RINm5F cells [11]. In addition, recent 
investigations indicate that NO promotes ER stress in 
insulin-producing cells [12]. 
The MAPKs, which include extracellular signal-
regulated kinase 1/2 (ERK1/2), c-Jun N-terminal 
protein kinase (JNK), ERK/big MAP kinase 1 (BMK1) 
and p38 kinase play various roles in cellular signal 
pathways induced by numerous extracellular signals. 
These kinases have been implicated in the control of 
several diverse biological processes, such as cell 
proliferation, differentiation and apoptosis. The β-cell 
MAP kinases are rapidly activated in response to the 
cytokines IL-1β and TNF-α [2,13,14]. According to a 
recent report, the MAPK pathway is also stimulated 
by NO [15]. Activation of the MAP kinases may 
promote β-cell death as inhibition of JNK protects β-
cell lines against IL-1β induced apoptosis [16,17] and 
human islets against the destruction mediated by IL-
1β, TNF-α and IFN-γ [18,19]. In addition, inhibition of 
p38 protected against cytokine-induced rat islet [14] 
and human islet cell death [20]. 
It has been shown that p38 activation can be 
carried out not only by its upstream MAPK kinase 
(MKK3/6) but also by p38 autophosphorylation [21]. 
P38 autophosphorylation requires interaction of p38 
with TAB1 [22]. TAB1 is a protein that was initially 
described as an activator of a member of MAPKK 
kinase TAK1 in response to stimulation of ΤGF-
β [23].  The C-terminal 68-amino acid portion of TAB1 
is sufficient for binding to and activation of TAK1 [24]. 
However, the portion of the TAB1 protein that is 
responsible for p38 interaction and activation is 
located N-terminal to the TAK1 binding site [21].   
We have recently observed that p38 is 
autophosphorylated in response to cytokines in 
insulin producing cells [20]. The aim of the present 
investigation was to study whether also NO promotes 
p38 autophosphorylation and whether this occurs via Int. J. Biol. Sci. 2007, 3  72
the TAB1-dependent mechanism. We report that p38 
phosphorylation is stimulated by TAB1 over-
expression and that this is paralleled by increased 
rates of cell death. 
2.  Material and methods 
Materials  
The chemicals were obtained from the following 
sources: [4-(4-fluorophenyl)-2-(4-methylsulfinyl-
phenyl)-5-(4-pyridyl) imidazole] (SB203580) was from 
Calbiochem (San Diego, CA, U.S.A.). Recombinant 
human IL-1β, and recombinant mouse IFN-γ were 
from PeproTech EC Ltd (London, UK). Polyclonal 
antibodies against p38 MAP Kinase, SAPK/JNK, 
phospho- (Thr180/Tyr182) p38, phospho- 
(Thr183/Tyr185) SAPK/JNK and phospho- 
(Thr202/Tyr204) p42/p44, were all from Cell Signal-
ing Technology (Beverly, MA, USA). Horseradish 
peroxidase-linked goat anti-rabbit Ig was from Amer-
sham International (Amersham, UK). Polyclonal 
ERK-1(C-16), TAB1 antibodies were from Santa Cruz 
Biotechnology (Santa Cruz, Ca, USA). Streptozotocin 
was from Sigma (Sigma, St.Louis, MO) and 
DETA/NO was from Alexis (CH, Lausen, Switzer-
land). 
Cell culture 
Β-TC6 cells at the passage number 20-30 
(American Tissue Culture Collection, Manassas, VA, 
USA) were maintained in D-MEM + 10% (vol/vol) 
fetal calf serum (FCS), benzylpenicilin (100 U/ml) 
and streptomycin (0.1 mg/ml) at 37°C and 5% CO2. 
 Overexpression of TAB1 in β-TC6 cells 
For transient expression 2-3 x 106  β-TC6 cells, 
which had been seeded the day before, were 
transfected with 0.5 μg pEGFP-C1 (Clonetech) + 2 μg 
pcDNA3-TAB1 using the combination of 9 μl 
Lipofectamine (Invitrogen) and 9 μl Lipofectamine 
Plus (Invitrogen) as described by the manufacturer. 
Control cells were transfected with 2.5 μg of pEGFP-
C1 only. The transfection mixture (200 μl) was 
dropped onto the cells which were in 1.5 ml serum-
free D-MEM. The cells were centrifuged for 10 min at 
600 g in a swing-out rotor. After 60 min at 37°C, the 
transfection medium was replaced with full culture 
medium. The day after transfection GFP-positive cells 
were sorted using a FACSCalibur flow cytometer 
(Becton-Dickinson). GFP-positive cells were identified 
by gating a region with high FL-1 intensity and 
normal size (FSC). In typical experiments 25-30 % of 
the cells were GFP-positive and 500000-550000 cells 
per group were collected. The sorted cells were then 
re-plated on cover slips in 24 well plates and cultured 
for another 24 hours. 
For stable expression of ΤΑΒ1, β-TC6 cells were 
transfected with pcDNA3-ΤΑΒ1 using Lipofectamine 
and Lipofectamine Plus reagents as described above. 
One day after the transfection G418 (300 μg/ml) was 
added. At day 6 the G418 dose was reduced to 150 
μg/ml. Resistant clones were picked after two weeks 
and analyzed for expression of ΤΑΒ1 by immunoblot 
analysis. 
Immunoblot analysis 
Β-TC6 cells (1x105) were washed in cold PBS and 
lysed in SDS-β-mercaptoethanol sample buffer 
containing 1 mM phenylmethyl sulfonyl-fluoride. 
Samples were then sonicated, boiled, separated on 9% 
SDS-polyacrylamide gels and electroblotted onto 
nitrocellulose filters. The filters were incubated with 
total p38 MAPK, total SAPK/JNK or total p42/p44 
ERK antibodies diluted 1:1000 in PBS supplemented 
with 2.5% bovine serum albumin. The filters were 
also incubated with phospho-specific p38, phospho-
specific SAPK/JNK and phospho-specific p42/44 
antibodies diluted 1:1000 in TBS supplemented with 
2.5% bovine serum albumin. In some experiments 
filters were probed for TAB1 (Santa Cruz). Stripping 
between the antibodies was performed by incubating 
for 40 min at 55°C in 2% SDS and 0.1 mM β-
mercaptoethanol. Horseradish peroxidase-linked goat 
anti-rabbit Ig was used as a second layer. The 
immunodetection was performed as described for the 
ECL immunoblotting detection system (Amersham 
International). The intensities of the bands were 
quantified by densitometric scanning using Kodak 
Digital Science ID software (Eastman Kodak, 
Rochester, NY, USA). 
Cell viability 
 β-TC6 cells transiently expressing GFP or 
TAB1+GFP were stained with propidium iodide (20 
µg/ml) for 15 min at 37°C. After careful washing to 
remove the fluorescent dye and to exclude 
trypsinisation artefacts, cells were trypsinzed and 
analyzed analyzed for red fluorescence (FL-3) by flow 
cytometry using the FACSCalibur instrument 
(Becton-Dickinson). Cells with intermediate 
fluorescence were gated as apoptotic and cells with 
high fluorescence were gated as necrotic [25]. The two 
forms of cell death were combined to total cell death. 
siRNA treatment of βTC-6 cells 
βTC-6 cells were transfected with siRNA 
directed against TAB1 or GL3 lucifierase as 
previously described [20]. TAB1 and GL3 luciferase 
siRNA was kindly provided by Dr. Jason W. Myers at 
the and Department of Biochemistry,  Stanford 
University School of Medicine, Stanford, CA, U.S.A. 
Two days after the transfection cells were incubated 
with DETA/NONOate (2 mM) for 30 min, which was 
followed by harvest of cells for immunoblot analysis 
as described above. 
3.  Results  
Effect of transient TAB1 overexpression on NO-
induced p38 phosphorylation and cell death 
We have recently demonstrated that cytokine-
induced  β-cell death involves p38 
autophosphorylation [20]. To evaluate whether NO 
acts via the same mechanism, and whether TAB1 
promotes such an event, we presently analyzed the 
putative role of TAB1 in the NO donor 
DETA/NONOate-induced p38 autophosphorylation. 
For this purpose we transiently transfected the β-TC6 
cells with GFP and TAB1 constructs. The FACS 
purified  β-TC6 cells were then exposed to the 
proinflammatory  cytokine IL-1β, NO donor 
DETA/NONOate and sorbitol for 20 minutes. All 
these treatments increased p38 phosphorylation 
(Figure 1, Panel A). Autophosphorylation of p38 at 
amino acids 180 and 182 was inhibited by the Int. J. Biol. Sci. 2007, 3  73
addition of SB203580. SB203580 is a pyridinyl 
imidazole compound that, by binding to the ATP-
binding site, selectively inhibits the α- and β-
isoforms of p38. In TAB1 overexpressing cells we 
observed an enhanced phosphorylation of p38 in 
response to IL-1β and DETA/NONOate (Figure 1, 
Panel A). In addition, both the IL-1β and the 
DETA/NONOate–induced p38 phosphorylation 
was partially counteracted by 10 μM SB203580. 
Hyperphosphorylation of p38 in response to 
sorbitol-induced osmotic stress was not affected 
by SB203580 in control or TAB1 expressing cells, 
indicating that the sorbitol pathway does not 
involve TAB1-induced p38 autophosphorylation.  
Fig.1. (A) Transient overexpession of TAB1 affects 
cytokine- and DETA/NO–induced p38 phosphorylation. 
Two days after transfection and 1 day after FACS 
sorting, the GFP positive cells were pretreated with 
SB203580 (10 μM) for 30 min and then stimulated with 
IL-1β (50 U/ml), DETA/NONOate (2.5 mM) and 
sorbitol (0.4 M) for 30 min. Cells were lysed, separated 
by SDS gel electrophoresis and analysed by 
immunoblotting with p38 and phospho-specific 
antibodies. The immunoblot is representative for two 
separate experiments. (B) Effect of 
TAB1 overexpression on DETA/NO-induced cell death 
in transiently transfected cells. Two days after 
transfection and 1 day after cell sorting, GFP-positive 
β-TC6 cells were exposed to DETA/NONOate (2.5 mM) 
for 24 h. Cells were then stained with propidium iodide 
and cell viability was assessed using the FACSCalibur 
flow cytometer. Results are presented as percentage of 
dead cells of the total cell count. Bars are means±S.E.M 
for three independent experiments. * denotes P<0.05 
using Student´s paired t-test. (C) Treatment with TAB1 
siRNA decreases DETA/NON-induced p38 
phosphorylation. Cells were transfected with GL3 
lucifierase siRNA (control) or TAB1 siRNA. Two days 
later cells were incubated with DETA/NONOate (2.5 
mM) for 30 min. Cells were lysed, separated by SDS 
gel electrophoresis and analysed by immunoblotting. 
The immunoblot is representative for two separate 
experiments. 
 
 
To establish whether TAB1 affects NO-
induced cell death, the transiently transfected β-
TC6 cells were exposed to DETA/NONOate for 24 
hours and propidium iodide uptake was assessed 
b y  f l o w  c y t o m e t r y .  W e  o b s e r v e d  t h a t  T A B 1  
overexpression did not affect the basal cell death 
rate. However, the NO–induced cell death rate 
was increased in TAB1 overexpressing cells 
(Figure 1, Panel B). 
Effect of TAB1 down-regulation on 
DETA/NONOate-induced p38 phosphorylation 
A genetic loss of function approach was also 
employed to investigate whether TAB1 
participates in nitric oxide-induced p38 activation. 
TAB1 levels were lowered by treatment with 
siRNA targeting TAB1 mRNA (Fig. 1C) and this 
was paralleled by a weaker nitric oxide-induced 
p38 phosphorylation as compared to control cells 
treated with GL3 luciferase siRNA (Fig. 1C). 
Effect of long-term TAB1 overexpression on p38, 
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To study the details of TAB1-induced MAPK 
activation in closer detail, we analyzed three separate 
β-TC6 cell clones (A2, A3 and D3) with the highest 
levels of TAB1 expression (Figure 2A). 
Phosphorylation of p38 was more pronounced in the 
TAB1 clones than in control cells, particularly at basal 
conditions (Figure 3, Panel A). As observed with the 
transiently transfected β-TC6 cells, the p38 inhibitor 
SB203580 partially counteracted NO induced p38 
phosphorylation, both in control and TAB1 clones. 
The DETA/NONOate-induced phosphorylation of 
JNK was not enhanced in the TAB1 cells as compared 
to control cells (Figure 3, Panel B). Instead, the 
inhibitory effect of SB203580 on p38 phosphorylation 
was paralleled by a stimulatory effect on the 
phosphorylation of JNK. Also the ERK 
phosphorylation was not affected by TAB1 
overexpression (Figure 3, Panel C). In this case, 
however, SB203580 decreased NO-induced ERK 
phosphorylation.  
Fig.2. TAB1 overexpression in stable 
cell clones. The β-TC6 cells were 
transfected for expression of TAB1 and 
neomycin resistance and selected by 
treatment with G418. After 10-14 days 
cells were lysed and analysed by 
immunoblot. The three clones A2, A3 
and D3 were selected for further 
experimentation.  
 
 
4.  Discussion 
It has been shown that NO plays a role for the β-
cell demise in the multi-low dose streptozotocin 
mouse, which is a model for Type 1 diabetes [26]. NO, 
produced following cytokine treatment, or supplied 
exogenously by donor molecules, induces DNA 
damage, inhibits islet oxidative metabolism, mediates 
islet morphological degeneration, and induces islet 
cell death [27,28]. Although the type of islet cell death 
– apoptosis or necrosis - has been debated [27-29], it is 
clear that NO participates in the development of 
diabetes in certain mouse models [26,30]. On the 
other hand, experiments with human islets have 
shown that despite an increase in NO production, 
cytokine-induced human islet functional impartment 
and cell death cannot be prevented by blockers of NO 
production [31,32]. Thus, the exact role and biological 
significance of NO for human β-cell destruction 
remains uncertain. 
We have recently reported that p38 activation is 
a necessary step in cytokine-induced rodent β-cell 
death [14,20]. As cytokines induce production of NO, 
we presently investigated the importance of and the 
mechanisms by which p38 is activated in response to 
NO. In the present paper we report (I) that high levels 
of NO activate p38, (II) that TAB1 augmented basal 
and NO-activated p38 phosphorylation, (III) that a 
lowering of TAB1 levels resulted in a weaker p38 
activation and (IV) that increased TAB1 levels were 
associated with increased NO-induced cell death. 
These findings are compatible with a view that TAB1 
plays a role in NO-induced p38 activation. TAB1 is a 
scaffold protein known to promote p38 
autophosphorylation without involvement of TAK1 
and MKK3/6 [21]. p38 autophosphorylation can be 
probed by using SB203580, an inhibitor that blocks 
p38 autophosphorylation but not MKK3/6-induced 
p38 phosphorylation. In the present study we 
consistently observed that SB203580 inhibits cytokine- 
and NO-induced p38 phosphorylation, but not 
sorbitol-induced p38 phosphorylation. This indicates 
that TAB1-stimulated p38 autophosphorylation 
represents the main p38-activating mechanism in 
response to cytokines and NO, but not to sorbitol. 
Using the insulin producing cell line INS-1, it 
was recently reported that the NO-donor SNAP 
activated both p38 and JNK, whereas ERK activity 
was suppressed or unaffected [15]. In our 
experimental setup the NO donor DETA/NONOate 
induced p38, JNK and ERK phosphorylation in β-TC6 
cells. This is in line with other studies using RINm5F 
cells, in which NO induced phosphorylation of ERK 
[33,34]. However, only the phosphorylation of p38, 
and not that of JNK or ERK, was presently enhanced 
in TAB1-overexpressing cells, indicating that NO-
induced JNK and ERK phosphorylation does not 
involve TAB1. Interestingly, inhibition of p38 with 
SB203580 resulted in enhanced JNK phosphorylation. 
This finding concurs with a previous demonstration 
o f  a  n e g a t i v e  f e e d  b a c k  m e c h a n i s m  i n  w h i c h  p 3 8  
phosphorylation of TAB1 results in suppression of 
TAK1-mediated JNK phosphorylation [35]. More 
surprising was that SB203580 inhibited not only p38, 
but also NO-induced ERK phosphorylation. At a 
concentration of 10 μM, SB203580 does not inhibit 
ERK [36]. Thus, it is likely that SB203580-induced 
inhibition of ERK results from p38 inhibition, 
indicating that NO-induced p38 activation promotes 
a secondary ERK activation.  
Activation of MAPK pathways in response to 
NO seems to occur in most cells, but the 
consequences of the different events probably differ 
from cell type to cell type. For example, ERK1/2 and 
p38 are activated by NO in colon cancer cells, but 
NO-induced apoptosis was mediated by p38 and not 
through ERK1/2 activation [37]. On the other hand, 
NO-mediated apoptosis in osteoblasts required JNK-
activity and not p38 [38]. Moreover, in RINm5F cells 
NO stimulated the phosphorylation of JNK and p38 
and selective inhibition of JNK, but not p38 or ERK, 
completely prevented β-cell recovery from NO-
mediated damage [33]. In the present investigation 
enhanced p38 activity was paralleled by increased 
NO-induced cell death in cells transiently 
overexpressing TAB1. 
It has been suggested that specific inhibitors of 
MAP kinases could be used for the treatment of 
inflammatory disorders, by inhibition of iNOS and Int. J. Biol. Sci. 2007, 3  75
NO production [39]. It may be a useful strategy also 
in the context of diabetes, considering the possible 
role of cytokines, NO and MAP kinases in the 
pathogenesis of Type 1 diabetes. However, due to 
the complex counter-regulatory mechanisms that are 
activated in response to MAP kinase inhibitors, such 
a pharmacological approach must be chosen with 
great care so that the activity of one MAP kinase is 
not replaced by another. 
Fig. 3. Effect of stable TAB1 overexpression on 
DETA/NO-stimulated p38, JNK and ERK 
phosphorylation. (A) The stable clones were pretreated 
with SB203580 (10 μM) and then stimulated with 
DETA/NO (2.5 mM) for 30 min. The cells were lysed, 
separated by SDS gel electrophoresis and analysed by 
immunoblotting with phospho-specific antibody 
recognizing phosphorylated p38 and total p38 (Panel A), 
phosphorylated JNK and total JNK (Panel B) or 
phosphorylated ERK and total ERK (Panel C). Values of 
phospho-protein bands were related to those of non-
phospho-specific protein bands. Results shown are 
means±S.E.M. for 3-6 observations. * denotes P<0.05 
using two-way ANOVA and Student´s t-test. 
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